News

FDA grants clearance to BrainStorm’s Phase IIIb trial of ALS treatment
The US Food and Drug Administration (FDA) has granted clearance to BrainStorm Cell Therapeutics to commence a Phase IIIb ...
Stocktwits on MSN9h
Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours
BrainStorm Cell Therapeutics saw rising retail chatter Monday when it obtained FDA clearance for Phase 3b clinical trials of ...
WFRV Local 5 on MSN12h
Local family shares experience with familial ALS and efforts to fund research to find a cure
In a story of resilience and hope, the Weber family stands as a reminder of the impact of familial bonds in the face of ...
ALS News Today20h
Neuronata-R improved function, survival in slow-progressing ALS
Patients given Neuronata-R who progressed more slowly saw significant gains in CAFS, slower declines in ALSFRS-R scores, and ...
Science Featured on MSN2d
Genetic Impact on ALS Progression
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive degeneration of motor neurons in the spinal cord and brain.
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) ...
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) said it scaled up its production of PrimeC to a commercial scale. PrimeC, ...